Keymed Biosciences Inc.

Keymed Biosciences Inc. is a comprehensive biopharmaceutical company focused on independent R&D and production of innovative drugs, dedicated to providing patients with more globally competitive, high-quality and affordable innovative therapies. Founded in 2016 and headquartered in Chengdu, it has branch offices in Beijing, Shanghai, Wuhan, Nanjing, Guangzhou and Jinan, with more than 1,600 employees, and listed on the Main Board of the Hong Kong Stock Exchange in 2021 (HKEX code: 02162). The company has built a differentiated, diversified pipeline across autoimmune diseases and oncology, with more than 50 research projects, over 30 self-developed Class 1 innovative drugs, and more than 10 candidate drugs in different clinical stages. Its core product, staphizumab (brand name: Kangyueda®, R&D code: CM310), is the first domestically developed and approved IL-4Rα antibody drug in China.

Keymed Biosciences Inc. was founded in 2016 and is headquartered in Chengdu, with branch offices in Beijing, Shanghai, Wuhan, Nanjing, Guangzhou and Jinan. Its founding team members are described as top experts in the international biopharmaceutical industry with world-class experience in translating scientific achievements and industrialization both domestically and internationally. In 2021, the company listed on the Main Board of the Hong Kong Stock Exchange (HKEX code: 02162). The company has built a differentiated, diversified pipeline across autoimmune diseases and oncology, with more than 50 research projects, over 30 self-developed Class 1 innovative drugs, and more than 10 candidate drugs in different clinical stages; two projects received support from the National "13th Five-Year Plan" "Major New Drug Creation" science and technology major project. Its core product, staphizumab (brand name: Kangyueda®, R&D code: CM310), received CDE breakthrough therapy drug designation; its marketing authorization application for treating moderate-to-severe atopic dermatitis in adults was approved by the National Medical Products Administration in September 2024, making it the first domestically developed and approved IL-4Rα antibody drug, filling the gap in domestic atopic dermatitis biologic products. Its marketing authorization application for treating chronic rhinosinusitis with nasal polyps was approved by the NMPA in December 2024, the first biologic in China for treating chronic rhinosinusitis with nasal polyps; its marketing authorization application for treating seasonal allergic rhinitis was approved in January 2025, the world's first IL-4Rα biologic for treating seasonal allergic rhinitis. All three indications have been included in the National Basic Medical Insurance, Maternity Insurance, and Work Injury Insurance Drug Catalog (2025). Another potential world-first Claudin 18.2-targeting antibody-drug conjugate, CMG901, received CDE breakthrough therapy drug designation, FDA Fast Track and Orphan Drug designations, and has reached a global exclusive licensing agreement worth approximately US$1.2 billion with AstraZeneca.

Leading innovator in innovative therapies for autoimmune diseases and other chronic diseases as well as oncology.

• Staphizumab (Kangyueda®, CM310)

  A high-efficiency, humanized monoclonal antibody targeting the interleukin-4 receptor alpha subunit (IL-4Rα); the first domestically developed and approved IL-4Rα antibody drug in China. By targeting IL-4Rα, it can dually block interleukin-4 (IL-4) and interleukin-13 (IL-13), two key cytokines that trigger type 2 inflammation, effectively curbing disease progression. Approved for moderate-to-severe atopic dermatitis in adults, chronic rhinosinusitis with nasal polyps, and seasonal allergic rhinitis.

• CMG901

  A potential world-first Claudin 18.2-targeting antibody-drug conjugate that received CDE breakthrough therapy drug designation, FDA Fast Track and Orphan Drug designations, and has reached a global exclusive licensing agreement worth approximately US$1.2 billion with AstraZeneca.

1. 1康悦达®（司普奇拜单抗）_ 康诺亚官网首页keymedbio.com
2. 2关于我们-康诺亚官网keymedbio.com
3. 3康悦达®(司普奇拜单抗)_首个国产IL-4Rα抗体 -康诺亚官网keymedbio.com
4. 4在研管线-康诺亚官网keymedbio.com
5. 5Keymed Biosciences Inc. (China)wikidata.org